BACKGROUND:Tenofovir (TDF) is associated with phosphaturia and elevated 1,25 dihydroxy vitamin D (1,25-OH(2)D). Fibroblast growth factor 23 (FGF23) causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D-binding protein (VDBP) binds to 1,25-OH(2)D, decreasing its biological activity, and is elevated in individuals with higher plasma tenofovir concentrations. We compared FGF23 and VDBP before and after vitamin D3 (VITD) supplementation in youths treated with combination antiretroviral therapy (cART) containing or not containing TDF. METHODS: A randomized controlled trial in HIV-positive youths aged 18-25 years enrolled participants based oncART treatment with TDF (TDF; n=118) or without TDF (no-TDF; n=85), and randomized within those groups to VITD (50,000 IU every 4 weeks) or placebo (PL). We measured FGF23 and VDBP and calculated free 1,25-OH(2)D at baseline and week 12, and compared changes by TDF treatment and VITD randomized group. RESULTS: At baseline, serum FGF23 concentration showed a quadratic relationship with 1,25-OH(2)D most pronounced in the TDF group. At week 12, total and free 1,25-OH(2)D increased in the VITD but not PL groups, independent of TDF use. FGF23 increased in the TDF group receiving VITD, but there was no FGF23 change in the no-TDF group receiving VITD or the PL groups. The adjusted mean change in FGF23 from baseline to week 12 was 7.7 pg/ml in the TDF/VITD group, compared with -1.7 (no-TDF/VITD, P=0.010), -1.3 (TDF/PL, P=0.006) and 1.1 (no-TDF/PL, P=0.035). CONCLUSIONS: These results suggest that TDF-containing cART may alter the FGF23 response to vitamin D supplementation in HIV-infected youths. Clinical trials number: NCT00490412.
RCT Entities:
BACKGROUND:Tenofovir (TDF) is associated with phosphaturia and elevated 1,25 dihydroxy vitamin D (1,25-OH(2)D). Fibroblast growth factor 23 (FGF23) causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D-binding protein (VDBP) binds to 1,25-OH(2)D, decreasing its biological activity, and is elevated in individuals with higher plasma tenofovir concentrations. We compared FGF23 and VDBP before and after vitamin D3 (VITD) supplementation in youths treated with combination antiretroviral therapy (cART) containing or not containing TDF. METHODS: A randomized controlled trial in HIV-positive youths aged 18-25 years enrolled participants based on cART treatment with TDF (TDF; n=118) or without TDF (no-TDF; n=85), and randomized within those groups to VITD (50,000 IU every 4 weeks) or placebo (PL). We measured FGF23 and VDBP and calculated free 1,25-OH(2)D at baseline and week 12, and compared changes by TDF treatment and VITD randomized group. RESULTS: At baseline, serum FGF23 concentration showed a quadratic relationship with 1,25-OH(2)D most pronounced in the TDF group. At week 12, total and free 1,25-OH(2)D increased in the VITD but not PL groups, independent of TDF use. FGF23 increased in the TDF group receiving VITD, but there was no FGF23 change in the no-TDF group receiving VITD or the PL groups. The adjusted mean change in FGF23 from baseline to week 12 was 7.7 pg/ml in the TDF/VITD group, compared with -1.7 (no-TDF/VITD, P=0.010), -1.3 (TDF/PL, P=0.006) and 1.1 (no-TDF/PL, P=0.035). CONCLUSIONS: These results suggest that TDF-containing cART may alter the FGF23 response to vitamin D supplementation in HIV-infected youths. Clinical trials number: NCT00490412.
Authors: S Pattanaungkul; B L Riggs; A L Yergey; N E Vieira; W M O'Fallon; S Khosla Journal: J Clin Endocrinol Metab Date: 2000-11 Impact factor: 5.958
Authors: Melanie M Rosenvinge; Keertie Gedela; Andrew J Copas; Anne Wilkinson; Catriona A Sheehy; Gul Bano; Phillip E Hay; Mark R Pakianathan; S Tariq Sadiq Journal: J Acquir Immune Defic Syndr Date: 2010-08 Impact factor: 3.731
Authors: Kathryn E Childs; Sarah L Fishman; Catherine Constable; Julio A Gutierrez; Christina M Wyatt; Douglas T Dieterich; Michael P Mullen; Andrea D Branch Journal: AIDS Res Hum Retroviruses Date: 2010-08 Impact factor: 2.205
Authors: Peter L Havens; Jennifer J Kiser; Charles B Stephensen; Rohan Hazra; Patricia M Flynn; Craig M Wilson; Brandy Rutledge; James Bethel; Cynthia G Pan; Leslie R Woodhouse; Marta D Van Loan; Nancy Liu; Jorge Lujan-Zilbermann; Alyne Baker; Bill G Kapogiannis; Catherine M Gordon; Kathleen Mulligan Journal: Antimicrob Agents Chemother Date: 2013-09-03 Impact factor: 5.191
Authors: Katherine Wesseling-Perry; Renata C Pereira; Shobha Sahney; Barbara Gales; He-Jing Wang; Robert Elashoff; Harald Jüppner; Isidro B Salusky Journal: Kidney Int Date: 2010-09-22 Impact factor: 10.612
Authors: Peter L Havens; Charles B Stephensen; Marta D Van Loan; Gertrud U Schuster; Leslie R Woodhouse; Patricia M Flynn; Catherine M Gordon; Cynthia G Pan; Brandy Rutledge; D Robert Harris; Georgine Price; Alyne Baker; William A Meyer; Craig M Wilson; Rohan Hazra; Bill G Kapogiannis; Kathleen Mulligan Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079
Authors: Justin Penner; Rashida A Ferrand; Ceri Richards; Kate A Ward; James E Burns; Celia L Gregson Journal: PLoS One Date: 2018-11-15 Impact factor: 3.240